Today's Rundown Bloodletting at Zymeworks as new CEO axes half of senior leaders, plans 25% reduction in headcount Merck's Clyburn headed for the exit, opening top human health spot at the New Jersey pharma giant Biden confident he can get 'big chunks' of $1.75T Build Back Better Act signed into law FDA urges doctors to prioritize blood draws as collection tube supplies dwindle Fierce JPM Week: AstraZeneca cancer R&D head marks Imfinzi as 'core backbone' of oncology strategy with the right combo—including treme Fierce JPM Week: Women are the 'power buyers' of healthcare. Here's how startups are striving to serve them Fierce JPM Week: Game recognizes game—Lilly, Novartis execs commend Pfizer on Paxlovid, but where does that leave them in the COVID market? Fierce JPM Week: How virtual-first plans are tackling the balance between in-person, digital care Fresh from $86M series A, Metis poaches Kala CSO to support move into the clinic Senators request FTC investigation into 'unfair, deceptive and harmful' COVID test price gouging Goodbye Humira, hello Dupixent: Sanofi and Regeneron outspend AbbVie to top 2021’s pharma TV ad spenders Artificial pancreas app delivers stronger control of Type 1 diabetes in toddlers and young children in Cambridge study No deal for GSK consumer health: Unilever stops raising $68B bid amid investor pushback Featured Story | By Nick Paul Taylor Kenneth Galbraith has made an immediate mark on Zymeworks. Days after taking up the CEO position, Galbraith has axed half the senior management team and disclosed plans to cut total headcount by 25%. read more |
| |
|---|
|
Top Stories By Fraiser Kansteiner Frank Clyburn is taking off to “assume a leadership opportunity with another company,” Merck said Thursday. A replacement to head up human health at Merck will be announced in the coming weeks, the company added. read more By Robert King President Joe Biden endorsed splitting up his $1.75 trillion Build Back Better Act, but it remains unclear what healthcare policies could survive such a piecemeal approach. read more By Conor Hale The agency had previously listed one specific type of blood collection tube in shortage—those containing the anticoagulant sodium citrate, typically identified by a light blue cap. Now, the FDA has expanded that list to include all specimen tubes. read more By Angus Liu In the increasingly crowded cancer immunotherapy field, AstraZeneca’s Imfinzi has mostly been used in stage III non-small cell lung cancer. But with the right combination strategy, the PD-L1 inhibitor has promise in other tumor types, AZ’s oncology R&D head said. read more By Heather Landi Women's health is now in the spotlight, and investors have been quick to put their cash into this growing market. What's next for women's health? Three executives—Hilary Coles, co-founder of Hims & Hers, Carolyn Witte, co-founder of Tia and Lynne Chou O'Keefe from Define Ventures—share their perspectives on the future of the market and why healthcare works better for everyone when it works for women. read more By Annalee Armstrong It’s not often that high profile pharmaceutical executives publicly laud a direct competitor’s medicine, but that’s what’s happening these days for Pfizer’s COVID-19 antiviral Paxlovid. read more By Paige Minemyer Amid the industry's telehealth boom, health insurers are putting a focus on the potential of virtual care through virtual-first plan designs. read more By Nick Paul Taylor Hongming Chen has ended her long affiliation with Kala Pharmaceuticals. Having been with Kala since its origins in 2010, Chen has left the chief scientific officer post to become head of R&D at a biotech that is just starting out. read more By Andrea Park In an additional effort to bring down the costs of COVID tests, Sen. Ed Markey sent another letter to test makers and retailers asking them to make the tests they make and sell more affordable. read more By Ben Adams AbbVie’s blockbuster giant, Humira, is used to being top dog in the pharma industry. But it had a rude awakening in 2021, when it’s massive $20 billion annual sales figure was shattered by Pfizer’s COVID-19 vaccine. And now, AbbVie's having to settle for the final podium place in the TV pharma ad spending world. read more By Conor Hale A program developed by researchers at the University of Cambridge showed it can safely help deliver insulin as it is needed—and be more effective at flattening curves in glucose readings compared to today’s devices. read more By Angus Liu GlaxoSmithKline’s consumer health unit won’t be bought out by Unilever: The British consumer goods giant refused to raise its $68 billion offer. But there are questions left for both companies. read more |
